Warning: mysql_query() [function.mysql-query]: Unable to save result set in /www/web/eversunny/public_html/includes/db.inc.php on line 51
Database error: Invalid SQL: select * from pwn_comment where pid='290834' and iffb='1' order by id limit 0,10
MySQL Error: 1030 (Got error 134 from storage engine)
#0 dbbase_sql->halt(Invalid SQL: select * from pwn_comment where pid='290834' and iffb='1' order by id limit 0,10) called at [/www/web/eversunny/public_html/includes/db.inc.php:55] #1 dbbase_sql->query(select * from {P}_comment where pid='290834' and iffb='1' order by id limit 0,10) called at [/www/web/eversunny/public_html/comment/module/CommentContent.php:181] #2 CommentContent() called at [/www/web/eversunny/public_html/includes/common.inc.php:524] #3 PrintPage() called at [/www/web/eversunny/public_html/comment/html/index.php:13]
Warning: mysql_fetch_array(): supplied argument is not a valid MySQL result resource in /www/web/eversunny/public_html/includes/db.inc.php on line 62
发布于:2019-4-2 20:16:56  访问:45 次 回复:0 篇
版主管理 | 推荐 | 删除 | 删除并扣分
The treatment of subjects with advanced melanoma were two distinctive studies
This effect has been also observed inside the treatment of non-squamous non mall-cell lung AZD-7762 In Vivo cancer (NSCLC) that had progressed through or right after platinum-based doublet chemotherapy [5]. Conclusions: The usage of nivolumab in some individuals could possibly imply a worse choice than chemotherapy. It remains a challenge to recognize those patients who could have a opportunity to advantage from nivolumab.References 1. Authorisation information for Opdivo. Accessible on: http://www.ema.europa. eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/ human_med_001876.jsp mid=WC0b01ac058001d124 (Retrieved October 23, 2015). 2. European public assessment report for Opdivo. Obtainable on: http://www. ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assess ment_report/human/003985/WC500189767.pdf (Retrieved October 23, 2015). three. Robert C, Lengthy GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320?0. four. Weber JS, D‘Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced mela noma who progressed soon after antiCTLA4 therapy (CheckMate 037): a randomised, controlled, openlabel, phase 3 trial. Lancet Oncol. 2015;16(four):375?four.J Transl Med 2016, 14(Suppl 1):SPage 7 of5. Borghaei H, PazAres L, Horn L, Spigel DR, Steins M, Prepared NE, et al. Nivolumab versus docetaxel in sophisticated nonsquamous nonsmallcell lung cancer. N Engl J Med. 2015;373(17):1627?9. six. European public assessment report for nivolumab. Offered on: http://www. ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_ report/human/003840/WC500190651.pdf (Retrieved October 23, 2015). 7. Brahmer J, Reckamp KL, Baas P, Crin?L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in sophisticated squamouscell nonsmallcell lung cancer. N Engl J Med. 2015;373(2):123?five.four. Radford M, Cortes P, Carrasco J, et al. Costeffectiveness of ipilimumab in previously treated sufferers for sophisticated melanoma in Portugal. Worth Overall health. 2013;16(3):A139. five. Linstone HA, Turoff M. The Delphi Approach: Techniques and Applications EBook. Newark: Institute of Technology. six.The therapy of subjects with sophisticated melanoma have been two different studies: study CA209037 [2, 3]: a phase 3 trial of nivolumab vs investigator‘s choice in sophisticated Melanoma sufferers progressing post anti-CTLA-4 therapy; and Study CA209069 [2, 4]: a phase three, study of nivolumab vs dacarbazine in subjects with BRAF wild sort, previously untreated. Nivolumab shown convincing statistically significant and clinically relevant results within the first-line treatment of metastatic PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28154141 melanoma. Unfortunately, mature data on OS will not be available, because only 34 of the events have occurred. On the other hand, it seems affordable to assume that the larger life expectancy related to nivolumab in initially line will probably be maintained. With regards to the use of nivolumab in final line, after failure of ipilimumab and/or BRAF inhibitors, good results happen to be observed for ORR and PFS though restricted to a subset of patients. On the other hand, the OS curves show an unexpected profile with all the lines crossing among six and 9 months. It seems plausible that the delay within the onset with the impact of nivolumab (three months) contributes to the higher price of deaths inside the nivolumab arm in the 1st three months of remedy.
共0篇回复 每页10篇 页次:1/1
共0篇回复 每页10篇 页次:1/1
验 证 码
Copyright (C) 2014-2016 All Rights Reserved. 爱屋阳光网上商城管理系统 版权所有 ICP15003708
联系地址:北京市昌平区火炬街21号莱特默勒大厦4层  邮政编码:102299